Gauthier S, Panisset M, Nalbantoglu J, Poirier J. Alzheimer’s diseae: current knowledge, management and research. Canadian Medical Association Journal 157(8):1047-1052; 1997.
Small GW, Rabins PV, Barry PP et al. Diagnosis and treatment of Alzheimer disease and related disorders. Consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer’s Association, and the American Geriatrics Society. Journal of the American Geriatric Associaton 278(16): 1363- 1371; 1997.
Aubert I, Araujo DM, Cecyre D et al. Comparative alterations of nicotinic and muscarinic binding sites in Alzheimer’s and Parkinson’s diseases. Journal of Neurochemistry, 58:529-541, 1992.
Giacobini E, Pharmacokinetic and pharmacologic considerations. In: Pharmacotherapy of Alzheimer’s Disease. Gauthier S, ed., London: Martin Dunitz Ltd;1998: In press.
Gauthier S, Bouchard R, Lamontagne A et al. Tetrahydroaminoacridine - lecithin combination therapy in patients with intermediate-stage Alzheimer’s disease. New England Journal of Medicine 322(18):1272-1276; 1990.
Grundman M, Thal LJ. Trial designs. In: Pharmacotherapy of Alzheimer’s Disease. Gauthier S, ed., London: Martin Dunitz Ltd;1998: In press.
Rockwood K, Beattie BL, Eastwood MR et al. A randomized, controlled trial of linopirdine in the treatment of Alzheimer’s disease. Canadian Journal of Neurological Sciences 24(2):140- 145; 1997.
Bodick NC, Offen WW, Levey AI et al. Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer’s disease. Archives of Neurology 54(4): 465-473; 1997.
Panisset M, Gauthier S. Outcome variables in research and in practice. In: Pharmacotherapy of Alzheimer’s Disease. Gauthier S, ed., London: Martin Dunitz Ltd;1998: In press.
Murali Doraiswamy P. Current cholinergic therapy for symtoms of Alzheimer’s disease. Primary Psychiatry 3: 3-11; 1996.
Gauthier S, Poirier J. Achievements and unresolved issues. In:
Pharmacotherapy of Alzheimer’s Disease. Gauthier S, ed.,
London: Martin Dunitz Ltd; 1998: In press.
Poirier J, Delisle MC, Quirion R et al. Apolipoprotein E4 allele
as a predictor of cholinergic deficits and treatment outcome in Alzheimer’s disease. Proceedings of the National Academic of Sciences USA 92(26):12260-12264, 1995.
Feldman H, Gracon S. Alzheimer’s disease: symptomatic drugs under development. In: Clinical Diagnosis and Management of Alzheimer’s Disease. Gauthier S, ed., London: Martin Dunitz Ltd; 1996: 239-259.
Rudolphi KA. Propentofylline - preclinical data. In Alzheimer Disease: From Molecular Biology to Therapy. Becker R, Giacobini E, eds., Boston: Birkhäuser; 1996: 355-359.
Aisen PS, Davis KL. The search for disease-modifying treatment for Alzheimer’s disease. Neurology 48(5 suppl 6): S35-S41; 1997.
McGeer EG and McGeer PL. Innate Inflammatory Reaction of the Brain in Alzheimer Disease. McGill Journal of Medicine 3(2): 134-141; 1998.
Leber P. Slowing the progression of Alzheimer disease: methodologic issues. Alzheimer Disease and Associated Disorders 11(suppl 5): S10-S21; 1997.
Sano M, Ernesto C, Thomas RG et al. A controlled trial of selegiline, alpha tocopherol, or both as treatment for Alzheimer’s disease. New England Journal of Medicine 336(17): 1216-1222; 1997.
Khachaturian Z. The five-five, ten-ten plan for Alzheimer’s disease. Neurobiology of Aging 13(2): 197-198; 1992.
Thal LJ, Carta A, Doody R et al. Prevention protocol for Alzheimer disease. Position paper from the International Working Group on Harmonization of Dementia Drugs Guidelines. Alzheimer Disease and Associated Disorders 11(suppl 3): 46-49; 1997.
Birge SJ. The role of estrogen in the treatment of Alzheimer’s disease. Neurology 48(5 suppl 7): S36-S41; 1997.
Canadian Study of Health and Aging. The Canadian Study of Health and Aging: risk factors for Alzheimer’s disease in Canada. Neurology 44(11): 2073-2080; 1994.
Gauthier S. Prevention of Alzheimer’s disease. Annales de Médecine Interne In press; 1998.
